AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge
DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.
The presidential candidate is the latest critic of current laws that prohibit the government from negotiating drug prices for Medicare Part D.
The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.